secwatch / observer
8-K filed February 23, 2023, 6:59 PM ET ticker COLL CIK 0001267565
earnings confidence high sentiment positive materiality 0.75

Collegium Q4 record net revenue $129.6M; FY22 adj. EBITDA $266.0M, reaffirms 2023 guidance

COLLEGIUM PHARMACEUTICAL, INC

2022-FY EPS reported -$0.74 revenue$463,933,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended December 31, 2022 results: revenue $129.6 million, net income $(7.2) million, EPS $(0.21) GAAP loss per share (basic and diluted). Guidance reaffirmed.

Period
the quarter ended December 31, 2022
Revenue
$129.6 million
Net income
$(7.2) million
EPS
$(0.21) GAAP loss per share (basic and diluted)
Guidance
reaffirmed
Result
reported results
Exact text from the filing
● Product revenues, net were $129.6 million for the quarter ended December 31, 2022 (the “2022 Quarter”), compared to $27.4 million for the quarter ended December 31, 2021 (the “2021 Quarter”). ● GAAP operating expenses were $38.0 million for the 2022 Quarter, compared to $32.8 million for the 2021 Quarter. Adjusted operating expenses, which exclude stock-based compensation expense of $5.7 million and acquisition related expenses of $0.1 million, were $32.3 million for the 2022 Quarter, compared to $20.4 million for the 2021 Quarter, which excluded stock-based compensation expense of $4.9 million, restructuring expenses of $4.6 million, and litigation settlements of $2.9 million. ● GAAP net loss for the 2022 Quarter was $(7.2) million, with $(0.21) GAAP loss per share (basic and diluted), compared to GAAP net loss for the 2021 Quarter of $(25.0) million, with $(0.73) GAAP loss per share (basic and diluted).
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COLLEGIUM PHARMACEUTICAL, INC reported the year ended December 31, 2022 results: revenue $463.9 million, net income $(25.0) million, EPS $(0.74) GAAP loss per share (basic and diluted). Guidance reaffirmed.

Period
the year ended December 31, 2022
Revenue
$463.9 million
Net income
$(25.0) million
EPS
$(0.74) GAAP loss per share (basic and diluted)
Guidance
reaffirmed
Result
reported results
Exact text from the filing
● Product revenues, net were $463.9 million for the year ended December 31, 2022 (“FY 2022”), compared to $276.9 million for the year ended December 31, 2021 (“FY 2021”). ● GAAP operating expenses were $176.2 million for FY 2022, compared to $133.0 million for FY 2021. Adjusted operating expenses, which exclude stock-based compensation of $22.9 million and acquisition related expenses of $31.3 million, were $122.0 million for FY 2022, compared to $101.2 million for FY 2021, which excluded stock-based compensation expense of $24.3 million, restructuring expenses of $4.6 million, and litigation settlements of $2.9 million. ● GAAP net loss for FY 2022 was $(25.0) million, with $(0.74) GAAP loss per share (basic and diluted), compared to GAAP net income for FY 2021 of $71.5 million, with $2.05 GAAP earnings per share (basic) and $1.86 GAAP earnings per share (diluted).
View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR
accession 0001558370-23-001897
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.